The preparation of porcine (Tyr-A14-2H) insulin and its characterization by mass spectrometry by Savoy, Luc-Alain et al.
Protein Engineering vol.2 no.4 pp.313-315, 1988
The preparation of porcine (Tyr-A14-2!!) insulin and its
characterization by mass spectrometry
Luc-Alain Savoy*, Pierre Vuagnat1, Keith Rose, John
Halstr^m2, KJavs H.j0rgensen and Karoly Kovacs2
Departement de Biochimie Metiicale, Centre Metlical Universitaire,
9 avenue de Champel, CH-1211 Geneva 4, 'Section de mathematique,
University dc Geneve, 2-4 rue du Lievre, CH-1211 Geneva 24, Switzerland
and 2Novo Research Institute, Novo A116, DK-2880 Bagsvaerd, Denmark
*To whom correspondence should be addressed
The title compound was prepared by catalytic deiodination
of (Tyr-A14-3-I) insulin with deuterium gas. Under special
conditions (large excess of PdO in CH3OD/D2O at pH 9.2)
developed to minimize problems due to poisoning of the
catalyst, deuterated insulin was produced in yields of about
35% after purification by reversed phase HPLC. For analysis,
the deuterated insulin was digested with V8 protease and was
shown by mass spectrometry to have incorporated deuterium
to an extent of 96.6 atom %, exclusively in a pentapeptide
containing Tyr A14. The title compound should prove useful
to those workers studying insulin by mass spectrometry, and
use of the method with tritium gas in place of deuterium
should permit the preparation of a specifically labelled
radioactive insulin analogue which behaves identically to the
natural hormone.
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Introduction
In comparison with polypeptides substituted with exogenous
elements (e.g. 125I), polypeptides which differ only from the
natural form in possessing a different isotopic distribution can
be expected to behave more authentically. In the case of insulin,
replacement of *H by 3H using semisynthetic techniques has
yielded analogues which have provided a considerable amount
of information on the pharmacokinetics of the hormone (Berger
et al., 1979). In addition, both radioactive analogues and
analogues possessing stable isotope substitutions have proved
useful in studying the degradation of the hormone in vitro in the
presence of insulin proteinase (Savoy et al., 1988). The sensitivity
of detection of peptides by mass spectrometry is now approaching
levels which would permit the use of stable-isotope labelled
analogues in pharmacokinetics experiments. Up to now, specific
isotope labelling of insulin has been confined to positions Gly-
A \ De-A"1, De-Alu, Phe-B1, Phe-B^4, Phe-B^, Tyr-B^ and Lys-
B29, and has involved semisynthesis or biosynthesis (Berger et
al., 1979; Misbin et al., 1981; Kaufmann etal., 1985; Savoy
et al., 1988). Therefore, methods are required which permit the
production of insulin analogues labelled with tritium and
deuterium in positions other than those easily accessible by
semisynthetic techniques, particularly in the A chain.
The metal-catalyzed replacement of iodine with hydrogen
A preliminary presentation of part of this work has been given at the 10th American
Peptide Symposium (Halstrflm et al., 1987).
isotopes is a frequently used method of preparing analogues of
peptides containing tyrosine (Brundish and Wade, 1981).
Unfortunately, when sulphur-containing amino acid residues are
present, catalyst poisoning and side reactions (desulphurization)
are to be expected. We find, however, that with increasing excess
of palladium catalyst, the deiodination reaction is favoured, so
that a practical preparation of (Tyr-A14-3-2H) insulin in a
substantial yield becomes feasible.
Materials and methods
All solvents and reagents were of analytical grade or better, and
were used without further purification unless otherwise stated.
Porcine insulin (monocomponent grade) was the product of
Novo, Denmark, palladium (II) oxide ('Gold label', 99.999%,
lot no. TM 04616LM) was from Aldrich, methanol-d, (>99.5
atom % D) from Sigma, deuterium gas (>99.5 atom % D) and
deuterium oxide (> 99.75 atom % D) were both from Merck.
Catalytic deiodination
(Tyr-A14-3-I) insulin was prepared by iodination of porcine
monocomponent insulin by the lactoperoxidase method (Thorell
and Johanson, 1971), and purified by a combination of anion
exchange chromatography on QAE-Sephadex A-25 and reversed
phase HPLC on C18 silica, as used earlier for isolation of highly
purified (Tyr-Al4-3-I) insulin (J^rgensen et al., 1982). The
material was found to be — 99 % pure by analytical reversed phase
HPLC.
Prior to catalytic deiodination, exchangeable hydrogen was
exchanged for deuterium. Thus, the iodo insulin (10 mg) was
dissolved in D2O (3 ml) by addition of dilute trifluoroacetic acid
to pH 3, and the solution was freeze-dried.
Catalytic deiodination was performed by dissolving the freeze-
dried product in CH3OD (1 ml), followed by 0.6 M NaHCO,
in D2O (1.6 ml) in a 5 ml round-bottom flask. After addition
of a teflon-coated magnetic stirring bar and PdO (1000 mg),
atmospheric air was removed by applying a slight vacuum. After
connection to the deuterium gas supply, the mixture was
vigorously stirred at ambient pressure and temperature for 1 h.
The catalyst was allowed to settle, and the supernatant
immediately filtered on Millex GV. The catalyst was washed once
with 1 ml 50% methanol. Removal of methanol in vacua from
the combined filtrates was followed by purification of the
deuterated insulin by semi-preparative isocratic reversed phase
HPLC using a 7 /im C18 100 A25 x 0.8 cm column and 36 vol.
% ethanol acidified with 0.06 vol. % trifluoroacetic acid. After
concentrating and freeze-drying the insulin-containing fraction,
the purity of the product (3 -4 mg) was found to be - 9 8 % by
analytical reversed phase HPLC on a Novapak C18 column, using
0.15 M ammonium sulphate, pH 3, with an acetonitrile gradient
(18 -45 %). The deuterated insulin co-eluted with porcine mono-
component insulin.
Deuterium content
In separate experiments, deuterated insulin and control
(undeuterated insulin), freed from zinc, were dissolved at a
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Table I. Incorporation of deuterium (2H) as measured by FAB/MS
Peptide Atom % 2W
A1'"
AS-12
A13-17
A18-21_B14-21
Bl-13
B14-21
g22-3O
-0.12
-0.54
96.60
0.89
1.26
0.20
1.30
0.11 (15)
0.28 (13)
0.08 (15)
0.79 (15)
1.99 (15)
0.65 (15)
0.40 (15)
The table shows values obtained for deuterium incorporation into various
peptides isolated by HPLC after digestion of deuterated insulin with V8
protease. The conditions of deuteration were those giving highest
incorporation (see Table II).
•Values are given ± the standard error of the mean (SEM). The number of
spectra used in each calculation is given in parentheses.
Table n . Incorporation
conditions
Conditions
pH = 4.2
Protic solvent
pH9.2
Protic solvent
pH9.2
Deuterated solvent
of deuterium (2H) into Tyr-A14 as i
Yield
(mol % insulin)
25-35
30-40
30-40
i function of
Atom % 2H
41
56
96.6
(Tyr-A14-3-I) insulin was catalytically deiodinated in the presence of
deuterium gas, under 3 sets of conditions: (i) As in Materials and methods,
but instead of 0.6 M NaHCC^, 0.5 M triethylammonium acetate was used,
and the mixture with methanol was adjusted to an apparent pH of 4.2 by
addition of acetic acid. Also, non-deuterated solvents were used, (ii) As in
Materials and methods, but using non-deuterated solvents, (iii) As in
Materials and methods. pH values are apparent pH, measured in the
aqueous-methanolic solution before and after the reaction, with a combined
glass electrode, adjusted with aqueous standard buffers. The yield of
deuterated insulin (isolated by reversed phase HPLC) is given based on
starting (Tyr-A 14-3-I) insulin. The degree of incorporation of deuterium into
Tyr-A is also shown.
concentration of 200 /tM in ammonium bicarbonate solution (1 %
w/v) and were digested with Staphylococcus aureus V8 protease
(Cooper Biomedical) at an enzyme: substrate ratio of 1:60 (w/w)
at 37°C for 4 h. After removal of solvent and ammonium
bicarbonate in a vacuum centrifuge (Speed Vac, Savant
Instruments), samples were subjected to reversed phase HPLC
and to analysis by fast atom bombardment mass spectrometry
(FAB/MS).
HPLC was performed on equipment previously described
(Rose et al., 1988) using either a /tBondapak C,o cartridge in a
Z module (Waters) or a Nucleosil 5 /xm C8 300 A 25 X 0.4 cm
column (Macherey Nagel) operated at a flow rate of 1 ml/min.
Solvent A was 1 g HPLC-grade trifluoroacetic acid (Pierce)
dissolved in 1 1 HPLC-grade water (MilliQ system), and Solvent
B was HPLC-grade acetonitrile (Merck). The column was
equilibrated with Solvent A, the sample was injected, and after
5 min at 100% Solvent A, a linear gradient (1 %/min for 50 min)
of Solvent B was applied. The effluent was monitored at 214 run,
and fractions absorbing at this wavelength were collected
manually. After solvent removal in the vacuum centrifuge,
samples were examined by mass spectrometry.
FAB/MS was performed as previously described (Savoy et al.,
1988). Bioassay was carried out by the mouse blood glucose
assay, using the international standard.
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Results and discussion
Deuterium content
From the method of deuteration employed, it was expected that
deuterium would be incorporated upon deiodination of the (Tyr-
A14-3-I) insulin. However, owing to the unfavourable kinetic
isotope effect, the atomic abundance of deuterium in the product
was expected to be lower than that of the deuterium gas used.
In addition, non-specific incorporation in other residues, in
particular tyrosine and histidine, could not be excluded a priori.
Mass spectrometry was employed to localize the label and to
quantify the degree of incorporation.
Digestion with V8 protease followed by HPLC permits
isolation of peptides covering all of the sequence of porcine insulin
(Rose et al., 1988). In order to obtain sufficient precision in the
measurement of isotopic abundance, the peptides produced by
V8 digestion were examined separately by FAB/MS, taking 13
or 15 spectra over the molecular ion region. Each fragment from
the deuterated insulin and from the control (undeuterated) was
examined twice in this way. The extent of deuteration was
calculated from these spectra. Table I shows the extent of
incorporation of deuterium into the peptides examined. The only
peptide found to have incorporated appreciable amounts of
deuterium was that containing residues A -A17, which includes
Tyr-A14. The sequence of the peptide, Leu-Tyr-Gln-Leu-Glu,
contains no other residues capable of incorporating deuterium
under the conditions employed, so we may deduce that incor-
poration into Tyr-A14 proceeded specifically. The possibility that
the mass increase (1 a.m.u.) of this peptide might have been due
to deamidation of residue Gln-A15 was excluded by subjecting
the peptide to electrophoresis at high voltage on paper at pH 6.5:
the peptide migrated with a relative mobility of —0.25 relative
to aspartic acid = — 1. This value is close to that calculated
(Offord, 1966) for the nondeamidated peptide (relative mobility
-0.34) and very different from that calculated for the deamidated
sequence (-0.64).
Catalytic deiodination
Table II shows the degree of incorporation of deuterium into Tyr-
A14 found under various conditions. Under the best conditions
tried, specific incorporation of 96.6 atom % 2H was achieved.
The most important parameters affecting the yield appear to
be the quantity and the quality of the PdO employed. The most
consistent yields were obtained using the grade of PdO specified
in Materials and methods. Lower ratios of PdO to iodo insulin,
such as the 1:1 ratio often employed in catalytic hydrogenations,
invariably resulted in extended reaction times and low yields.
Furthermore, if the reaction is allowed to continue beyond the
point where about 10% of iodo insulin remains (HPLC), the
insulin peak will decline, and eventually disappear altogether.
This indicates the occurrence of competing reactions, e.g.
irreversible adsorption to the catalyst, possibly after reduction
of disulphide bridges. In the semi-preparative HPLC purification
the only major impurity observed is remaining iodo insulin. One
explanation for the apparently very simple composition of the
reaction mixture might be the removal of degraded insulins by
catalyst adsorption.
The potency of the product showing the highest incorporation
of deuterium was assayed on an aliquot of a 1 mg/ml solution,
the exact insulin concentration of which was determined by
quantitative amino acid analysis. Potency found: 29.3 IU/mg
(95% confidence limits: 34.2-25.1 IU/mg). The corresponding
value for anhydrous and salt-free porcine monocomponent
insulin is 29.0 IU/mg.
Preparation and characterization of (Tyr-A14-2^ insulin
Conclusion
Using a special palladium catalyst under particular conditions,
it is possible to produce insulin deuterated specifically at Tyr
A14 by deiodination of the appropriate precursor. It would be
expected that similar conditions, with appropriate precursors,
would permit the preparation of insulin analogues deuterated
specifically at any of the other three tyrosine residues.
By using tritium gas in place of deuterium, it should be possible
to prepare specifically labelled insulin analogues of relatively high
specific activity (15 Ci/mmol for 50% incorporation of one 3H),
analogues which should behave authentically.
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Note added in proof
By using tritium gas in place of deuterium, a labelled insulin analogue of relatively
high specific activity (10-15 Ci/mmole) has been prepared (Halstrem, J0rgensen
and Kovacs, 1988, Abstract no.45, presented at 20th European Peptide Sym-
posium Tubingen).
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